Please assess the completion status of the following clinical trial:

Trial Title: Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed advanced non-small cell lung cancer (NSCLC)~* Disease must have progressed after at least 2 prior chemotherapy regimens for NSCLC~* Patients must have measurable or nonmeasurable disease~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~* Bilirubin no greater than 1.5 times upper limit of normal (ULN)~* AST and ALT no greater than 3 times ULN (5 times ULN in patients with liver disease)~* Creatinine less than 1.5 times ULN or calculated creatinine clearance greater than 50 mL/min~* More than 3 weeks since prior chemotherapy, radiotherapy, immunotherapy or other investigational drug use~* Recovered from all prior therapy~* Fertile patients must use effective contraception~* Age \>= 18~* ECOG performance status of 0-1~Exclusion Criteria:~* Prior primary or metastatic brain or meningeal tumors unless clinically and radiographically stable and off therapy for at least 2 months~* Active second malignancy~* Clinically evident congestive heart failure, serious cardiac arrhythmias, or symptoms of coronary heart disease~* Prior radiotherapy to the only site of measurable or evaluable disease unless there is evidence of disease progression in that site~* Prior exposure to a ras pathway inhibitor (e.g., farnesyl transferase inhibitor)~* Concurrent medications known to be metabolized by the liver with a narrow therapeutic index, including the following:~  * Ketoconazole~ * Itraconazole~ * Quinidine~ * Digoxin~ * Cyclosporine~ * Ritonavir~ * Grapefruit products~ * Carbamazepine~ * Phenytoin~ * Phenobarbital~* Pregnant or nursing~* Clinically serious active infection~* Medical conditions, substance abuse or psychological/social situation that would preclude study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Induction then Sorafenib (Type: EXPERIMENTAL): Induction: All patients receive oral sorafenib twice daily on days 1-28. Treatment continues for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable disease proceed to randomization. Patients with responding disease continue to receive sorafenib for up to 1 year in the absence of disease progression.~Randomization: Patients with stable disease after the induction treatment were randomized to either the sorafenib arm or the placebo arm. Patients on the sorafenib arm receive sorafenib twice daily for up to 1 year in the absence of disease progression or unacceptable disease.
- Induction then Placebo then Sorafenib (Type: PLACEBO_COMPARATOR): Induction: All patients receive oral sorafenib twice daily on days 1-28. Treatment continues for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable disease proceed to randomization. Patients with responding disease continue to receive sorafenib for up to 1 year in the absence of disease progression.~Randomization: Patients with stable disease after the induction treatment were randomized to either the sorafenib arm or the placebo arm. Patients on the placebo arm receive oral placebo twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients on the placebo arm who develop disease progression within 1 year after randomization may cross over to sorafenib arm.
- Induction, not randomized (Type: OTHER): Induction: All patients receive oral sorafenib twice daily on days 1-28. Treatment continues for 2 cycles in the absence of disease progression or unacceptable toxicity.~Post-induction: Patients with responding disease or disease progression were not randomized in Step 2. Patients with responding disease continue to receive sorafenib for up to 1 year in the absence of disease progression, while patients with disease progression were removed from the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).